Disease X
The 100 Days Mission to End Pandemics
Versandkostenfrei!
Versandfertig in 1-2 Wochen
25,99 €
inkl. MwSt.
Weitere Ausgaben:
PAYBACK Punkte
13 °P sammeln!
"DISEASE X sets out a game-changing plan for how the world can learn from Covid-19 and be ready for the next pandemic." - Tony Blair, former British Prime Minister DISEASE X is a fast-paced, almost real-time account of how international scientists and global public health leaders are preparing the world to be able to contain outbreaks of new and re-emerging infectious diseases before they become global contagions. Disease X is the codename given by the World Health Organisation to a pathogen currently unknown to science with the potential to cause havoc to humankind. Emerging infections - such...
"DISEASE X sets out a game-changing plan for how the world can learn from Covid-19 and be ready for the next pandemic." - Tony Blair, former British Prime Minister DISEASE X is a fast-paced, almost real-time account of how international scientists and global public health leaders are preparing the world to be able to contain outbreaks of new and re-emerging infectious diseases before they become global contagions. Disease X is the codename given by the World Health Organisation to a pathogen currently unknown to science with the potential to cause havoc to humankind. Emerging infections - such as the recent outbreaks of new variants of H5N1 bird flu and mpox - are sending us multiple warnings that another Disease X is looming. New pathogens are occurring at an increasing cadence: we had SARS in 2002, H5N1 bird flu in 2004, H1N1 'swine flu' in 2009, MERS in 2012, Ebola in 2014, Zika in 2015, Covid-19 in 2019, and now mpox in Africa and a new H5N1 avian flu that has infected livestock. Written by a long-standing ex-Reuters global health and science correspondent, DISEASE X uses privileged access to the body leading international efforts to control viral outbreaks, the Coalition for Epidemic Preparedness Innovations (CEPI), and its CEO, Dr Richard Hatchett. CEPI seed-funded three successful COVID vaccines, including the AstraZeneca and Moderna shots. Weaving in insights from the likes of Bill Gates, Erna Solberg, Jeremy Farrar and Seth Berkley, the book explores the emergence of the novel coronavirus and the deadly crisis it caused. It analyses the responses of global health organisations and experts, including the WHO; national governments in Britain, China and the USA; COVAX, the global vaccine allocation facility; pharmaceutical companies; and leading research scientists. Ultimately, DISEASE X tells how, throughout the devastation of Covid, science and human ingenuity have shown that the world can devise intricate new weapons at a breathtaking pace against new deadly diseases. It tells how the world's public health scientists are embarking on a 100 Days Mission to embed that scientific progress into a pandemic-busting plan to defuse future threats from as-yet-unknown pathogens in a little over three months. This is the 100 Days Mission - backed by the G7 and G20 - that will see a newly prepared world move at speed to snuff out future threats before they become deadly pandemics. Foreword by the former UK PM Tony Blair. Reviews "An engaging, accessible and ultimately optimistic account of how nations, institutions and the scientific community responded to Covid and how they could work together in future." - Fergus Walsh, BBC Medical Editor "As Kelland argues cogently, fear of the next outbreak should not paralyse us but instead galvanise us into making sure the terrible toll of Covid-19 is not repeated. DISEASE X is a valuable policy roadmap in a world custom-built for pandemics." - Anjana Ahuja, co-author of Spike: The Virus Vs The People "With access to key players on the frontlines, DISEASE X takes us inside the effort to prevent future outbreaks from exploding into global disasters... this important book outlines why it will be vital to keep pandemic threats at the top of our priority list for decades to come." - James Paton, former Health Correspondent for Bloomberg News
Andere Kunden interessierten sich für
